Liposomal nanomedicines

Bibliography

• Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22
   PubMed Web of Science ®Google Scholar
• Abraham SA, Waterhouse DN, Mayer LD, et al. The liposomal formulation of doxorubicin. Methods Enzymol 2005;391:71-97
   PubMed Web of Science ®Google Scholar
• Boman NL, Masin D, Mayer LD, et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994;54:2830-3
   PubMed Web of Science ®Google Scholar
• Hope MJ, Wong KF. Liposomal formulation of ciprofloxacin. In: Shek PN, editor. Liposomes in Biomedical Applications. Harwood Academic Publishers, London; 1995:121-34
   Google Scholar
• Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol 2005;391:7-40
   PubMed Web of Science ®Google Scholar
• Mui B, Raney SG, Semple SC, Hope MJ. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther 2001;298:1185-92
   PubMed Web of Science ®Google Scholar
• Vollmer J, Janosch A, Laucht M, et al. Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev 2002;12:165-75
   PubMedGoogle Scholar
• Wilson KD, Raney SG, Sekirov L, et al. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol 2007;7:1064-75
   PubMed Web of Science ®Google Scholar
• De Jong S, Chikh G, Sekirov L, et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother 2007;56:1251-64
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-4
   PubMed Web of Science ®Google Scholar
• Chakraborty C. Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing. Curr Drug Targets 2007;8:469-82
   PubMed Web of Science ®Google Scholar
• Cullis PR, Hope MJ, Bally MB, et al. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1997;1331:187-211
   PubMed Web of Science ®Google Scholar
• Abraham SA, Edwards K, Karlsson G, et al. Formation of transition metal–doxorubicin complexes inside liposomes. Biochim Biophys Acta 2002;1565:41-54
   PubMed Web of Science ®Google Scholar
• Abraham SA, Edwards K, Karlsson G, et al. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Rel 2004;96:449-61
   PubMed Web of Science ®Google Scholar
• Semple SC, Leone R, Wang J, et al. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci 2005;94:1024-38
   PubMed Web of Science ®Google Scholar
• Ambegia E, Ansell S, Cullis P, et al. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 2005;1669:155-63
   PubMed Web of Science ®Google Scholar
• Liang MT, Davies NM, Toth I. Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int J Pharm 2005;301:247-54
   PubMed Web of Science ®Google Scholar
• Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006;113:9-14
   PubMed Web of Science ®Google Scholar
• Vyas SP, Rawat M, Rawat A, et al. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha. Drug Dev Ind Pharm 2006;32:699-707
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52
   PubMed Web of Science ®Google Scholar
• Bangham AD. Membrane models with phospholipids. Prog Biophys Mol Biol 1968;18:29-95
   PubMedGoogle Scholar
• Bangham AD. Liposomes: realizing their promise. Hosp Pract (Off Ed) 1992;27:51-6, 61-2
   PubMed Web of Science ®Google Scholar
• Bangham AD. Surrogate cells or Trojan horses. The discovery of liposomes. Bioessays 1995;17:1081-8
   PubMed Web of Science ®Google Scholar
• Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 1986;858:161-8
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005;16:691-707
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000;65:271-84
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207
   PubMedGoogle Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Rel 2001;74:47-61
   PubMed Web of Science ®Google Scholar
• Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215-20
   PubMed Web of Science ®Google Scholar
• Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6
   PubMed Web of Science ®Google Scholar
• Madden TD, Janoff AS, Cullis PR. Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol. Chem Phys Lipids 1990;52:189-98
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 1986;857:123-6
   PubMed Web of Science ®Google Scholar
• Mayer LD, Tai LC, Bally MB, et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1990;1025:143-51
   PubMed Web of Science ®Google Scholar
• Mayer LD, Tai LC, Ko DS, et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989;49:5922-30
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Wong KF, Redelmeier TE, et al. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1993;1149:329-38
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Loughrey H, et al. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990;50:575-9
   PubMed Web of Science ®Google Scholar
• Mayer LD, Nayar R, Thies RL, et al. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 1993;33:17-24
   PubMed Web of Science ®Google Scholar
• Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1993;1152:253-8
   PubMed Web of Science ®Google Scholar
• Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 1995;72:896-904
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004;53:329-36
   PubMed Web of Science ®Google Scholar
• White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95:822-8
   PubMed Web of Science ®Google Scholar
• Kim ES, Lu C, Khuri FR, et al. A Phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001;34:427-32
   PubMed Web of Science ®Google Scholar
• Madden TD, Harrigan PR, Tai LC, et al. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 1990;53:37-46
   PubMed Web of Science ®Google Scholar
• Lasic DD, Frederik PM, Stuart MC, et al. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992;312:255-8
   PubMed Web of Science ®Google Scholar
• Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201-15
   PubMed Web of Science ®Google Scholar
• Webb MS, Boman NL, Wiseman DJ, et al. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother 1998;42:45-52
   PubMed Web of Science ®Google Scholar
• Lasic DD, Ceh B, Stuart MC, et al. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995;1239:145-56
   PubMed Web of Science ®Google Scholar
• Maurer-Spurej E, Wong KF, Maurer N, Fenske DB, Cullis PR. Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. Biochim Biophys Acta 1999;1416:1-10
   PubMed Web of Science ®Google Scholar
• Maurer N, Wong KF, Hope MJ, Cullis PR. Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. Biochim Biophys Acta 1998;1374:9-20
   PubMed Web of Science ®Google Scholar
• Li X, Hirsh DJ, Cabral-Lilly D, et al. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta 1998;1415:23-40
   PubMed Web of Science ®Google Scholar
• Johnston MJ, Semple SC, Klimuk SK, et al. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 2006;1758:55-64
   PubMed Web of Science ®Google Scholar
• Fenske DB, Wong KF, Maurer E, et al. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim Biophys Acta 1998;1414:188-204
   PubMed Web of Science ®Google Scholar
• Wheeler JJ, Veiro JA, Cullis PR. Ionophore-mediated loading of Ca2+ into large unilamellar vesicles in response to transmembrane pH gradients. Mol Membr Biol 1994;11:151-7
   PubMed Web of Science ®Google Scholar
• Zhigaltsev IV, Maurer N, Akhong QF, et al. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Rel 2005;104:103-11
   PubMed Web of Science ®Google Scholar
• Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing Phase II trial. Ann Oncol 2000;11:69-72
   PubMed Web of Science ®Google Scholar
• Rodriguez MA, Sarris A, East K, et al. A Phase II study of liposomal vincristine in CHOP with rituximab for elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2002;21:Abstract 1132
   Google Scholar
• Rodriguez MA, Dang NH, Fayad L, et al. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): follow-up results of a Phase II study. J Clin Oncol 2004;22:8080
   Google Scholar
• Boehlke L, Winter JN. Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opin Biol Ther 2006;6:409-15
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Cheung BC, Sun TH, Leenhouts JM, Cullis PR. Loading of doxorubicin into liposomes by forming Mn2+–drug complexes. Biochim Biophys Acta 1998;1414:205-16
   PubMed Web of Science ®Google Scholar
• Chiu GN, Abraham SA, Ickenstein LM, et al. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Rel 2005;104:271-88
   PubMed Web of Science ®Google Scholar
• Taggar AS, Alnajim J, Anantha M, et al. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Rel 2006;114:78-88
   PubMed Web of Science ®Google Scholar
• Zhigaltsev IV, Maurer N, Edwards K, et al. Formation of drug–arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Rel 2006;110:378-86
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo Z, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66:3271-7
   PubMed Web of Science ®Google Scholar
• Johnston MJ, Semple SC, Klimuk SK, et al. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 2007;1768:1121-7
   PubMed Web of Science ®Google Scholar
• Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv 2005;2:341-51
   PubMedGoogle Scholar
• Abraham SA, McKenzie C, Masin D, et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 2004;10:728-38
   PubMed Web of Science ®Google Scholar
• Tardi PG, Gallagher RC, Johnstone S, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta 2007;1768:678-87
   PubMed Web of Science ®Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006;5:1854-63
   PubMed Web of Science ®Google Scholar
• Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 2005;7:E61-77
   PubMed Web of Science ®Google Scholar
• Fenske DB, Maclachlan I, Cullis PR. Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 2001;3:153-8
   PubMed Web of Science ®Google Scholar
• Wheeler JJ, Palmer L, Ossanlou M, et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 1999;6:271-81
   PubMed Web of Science ®Google Scholar
• Tam P, Monck M, Lee D, et al. Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther 2000;7:1867-74
   PubMed Web of Science ®Google Scholar
• Fenske DB, Maclachlan I, Cullis PR. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol 2002;346:36-71
   PubMed Web of Science ®Google Scholar
• Fenske DB, Maurer N, Cullis PR. Encapsulation of weakly-basic drugs, antisense oligonucleotides, and plasmid DNA within large unilamellar vesicles for drug delivery applications. In: Torchilin VP, Weissig V, editors. Liposomes: A Practical Approach. Oxford: Oxford University Press, 2003. p. 167-91
   Google Scholar
• Zhang YP, Sekirov L, Saravolac EG, et al. Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther 1999;6:1438-47
   PubMed Web of Science ®Google Scholar
• Maurer N, Wong KF, Stark H, et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 2001;80:2310-26
   PubMed Web of Science ®Google Scholar
• Semple SC, Klimuk SK, Harasym TO, et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 2001;1510:152-66
   PubMed Web of Science ®Google Scholar
• Stuart DD, Semple SC, Allen TM. High efficiency entrapment of antisense oligonucleotides in liposomes. Methods Enzymol 2004;387:171-88
   PubMed Web of Science ®Google Scholar
• Jeffs LB, Palmer LR, Ambegia EG, et al. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 2005;22:362-72
   PubMed Web of Science ®Google Scholar
• Fenske DB, Palmer LR, Chen T, et al. Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells. Biochim Biophys Acta 2001;1512:259-72
   PubMed Web of Science ®Google Scholar
• Palmer LR, Chen T, Lam AM, et al. Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. Biochim Biophys Acta 2003;1611:204-16
   PubMed Web of Science ®Google Scholar
• Heyes J, Palmer L, Bremner K, Maclachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Rel 2005;107:276-87
   PubMed Web of Science ®Google Scholar
• Heyes J, Palmer L, Chan K, et al. Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA. Mol Ther 2007;15:713-20
   PubMed Web of Science ®Google Scholar
• Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86
   PubMed Web of Science ®Google Scholar
• Kong Y, Ruan L, Ma L, et al. RNA interference as a novel and powerful tool in immunopharmacological research. Int Immunopharmacol 2007;7:417-26
   PubMed Web of Science ®Google Scholar
• Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. Mol Aspects Med 2007;28:143-66
   PubMed Web of Science ®Google Scholar
• Sioud M. RNA interference and innate immunity. Adv Drug Deliv Rev 2007;59:153-63
   PubMed Web of Science ®Google Scholar
• Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988;48:2659-68
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193:1650-7
   PubMed Web of Science ®Google Scholar
• Heeg K, Sparwasser T, Lipford GB, et al. Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Eur J Clin Microbiol Infect Dis 1998;17:464-9
   PubMed Web of Science ®Google Scholar
• Lipford GB, Heeg K, Wagner H. Bacterial DNA as immune cell activator. Trends Microbiol 1998;6:496-500
   PubMed Web of Science ®Google Scholar
• Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003;198:513-20
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9
   PubMed Web of Science ®Google Scholar
• Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5
   PubMed Web of Science ®Google Scholar
• Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001;98:9237-42
   PubMed Web of Science ®Google Scholar
• Kirschning CJ, Bauer S. Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses. Int J Med Microbiol 2001;291:251-60
   PubMed Web of Science ®Google Scholar
• Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11:263-70
   PubMed Web of Science ®Google Scholar
• Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005;348:1079-90
   PubMed Web of Science ®Google Scholar
• Judge AD, Bola G, Lee AC, Maclachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo Mol Ther 2006;13:494-505
   PubMed Web of Science ®Google Scholar
• Monteith DK, Henry SP, Howard RB, et al. Immune stimulation – a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 1997;12:421-32
   PubMedGoogle Scholar
• Boggs RT, McGraw K, Condon T, et al. Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev 1997;7:461-71
   PubMedGoogle Scholar
• Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-54
   PubMed Web of Science ®Google Scholar
• Chu RS, Targoni OS, Krieg AM, et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997;186:1623-31
   PubMed Web of Science ®Google Scholar
• Elkins KL, Rhinehart-Jones TR, Stibitz S et al. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999;162:2291-8
   PubMed Web of Science ®Google Scholar
• Klinman DM, Conover J, Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 1999;67:5658-63
   PubMed Web of Science ®Google Scholar
• Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001;167:3324-8
   PubMed Web of Science ®Google Scholar
• Allen TM, Sapra P, Moase E, Moreira J, Iden D. Adventures in targeting. J Liposome Res 2002;12:5-12
   PubMed Web of Science ®Google Scholar
• Allen TM, Mumbengegwi DR, Charrois GJ. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567-73
   PubMed Web of Science ®Google Scholar
• Cheng WW, Das D, Suresh M, Allen TM. Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochim Biophys Acta 2007;1768:21-9
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 2003;9:4595-605
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66:10073-82
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-62
   PubMed Web of Science ®Google Scholar
• Sapra P, Moase EH, MA J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab’ fragments. Clin Cancer Res 2004;10:1100-11
   PubMed Web of Science ®Google Scholar
• Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2:369-81
   PubMedGoogle Scholar
• Chen T, McIntosh D, He Y, et al. Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents. Mol Membr Biol 2004;21:385-93
   PubMed Web of Science ®Google Scholar
• Finn J, Lee AC, Maclachlan I, Cullis P. An enhanced autogene-based dual-promoter cytoplasmic expression system yields increased gene expression. Gene Ther 2004;11:276-83
   PubMed Web of Science ®Google Scholar
• Finn J, Maclachlan I, Cullis P. Factors limiting autogene-based cytoplasmic expression systems. FASEB J 2005;19:608-10
   PubMedGoogle Scholar
• Tekmira Pharmaceuticals Available from: www.inexpharm.com [Accessed 5th December 2007]
   Google Scholar
• Hana Biosciences Available from: www.hanabiosciences.com [Accessed 5th December 2007]
   Google Scholar
• Aradigm Corporation Available from: www.aradigm.com [Accessed 5th December 2007]
   Google Scholar
• Pfizer Available from: www.pfizer.com/home [Accessed 5th December 2007]
   Google Scholar
• Alnylam Pharmaceuticals Available from: www.alnylam.com [Accessed 5th December 2007]
   Google Scholar
• Alza Available from: www.alza.com [Accessed 5th December 2007]
   Google Scholar
• Antigenics Available from: www.antigenics.com [Accessed 5th December 2007]
   Google Scholar
• Celsion Corporation Available from: www.celsion.com [Accessed 5th December 2007]
   Google Scholar
• Gilead Available from: www.gilead.com [Accessed 5th December 2007]
   Google Scholar
• Enzon Pharmaceuticals Available from: www.enzon.com [Accessed December 2007]
   Google Scholar
• Samaritan Pharmaceuticals Available from: www.samaritanpharma.com [Accessed December 2007]
   Google Scholar
• Three Rivers Pharmaceuticals Available from: www.3riverspharma.com [Accessed December 2007]
   Google Scholar
• Diatos Available from: www.diatos.com [Accessed December 2007]
   Google Scholar
• Sopherion Therapeutics Available from: www.sopherion.com [Accessed December 2007]
   Google Scholar